ArticleCancer medicine2026
Prognostic Nomogram for Ovarian Cancer Patients on First-Line Maintenance Therapy With PARP Inhibitors: A Retrospective Cohort Study.
Article in Cancer medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
objectiveTo develop and validate a prognostic nomogram that integrates clinical variables and biomarker statuses for predicting progression-free survival (PFS) and overall survival (OS) in patients with advanced epithelial ovarian cancer (OC) receiving first-line poly (ADP-ribose) polymerase inhibitor (PARPi) maintenance therapy.
methodsClinical data from 145 OC patients who received first-line PARPi maintenance therapy from August 2018 to May 2024 were retrospectively analyzed. Univariate and multivariate regression analyses were performed to identify the predictive factors. A nomogram was constructed using a multivariate Cox regression model.
resultsPatients with OC who received first-line PARPi maintenance treatment showed improved PFS (median PFS: 48.53 months) and OS. Cox regression analysis identified several independent prognostic factors for prolonged PFS, including BRCA mutations, R0 resection (no residual disease), FIGO stage III (vs. IV), and a higher CA-125 elimination rate constant (KELIM) score (KELIM > 1). Additionally, BRCA mutations and younger age were significant predictors of better OS. Analysis of subsequent treatment in patients who experienced recurrence revealed that platinum-based second-line chemotherapy combined with bevacizumab improved outcomes, whereas a longer duration of PARPi therapy (> 12 months) appeared to be associated with poorer prognosis.
conclusionThis study establishes and validates the nomogram that integrates clinical factors (FIGO Stage, Residual Disease, and Age) with biomarkers (BRCA and KELIM) to predict outcomes in patients with advanced OC receiving First-Line PARPi maintenance therapy. Furthermore, our finding suggest that an extended duration of PARPi treatment may be a risk factor for subsequent treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.